Showing only trials that are Yorkshire and the Humber

Study to Evaluate the Efficacy and Safety of Sonrotoclax in Participants With Waldenström’s Macroglobulinemia

Understanding the safety and efficacy of a new drug that stops a certain type of protein working

Expected to end: 01/09/2028

A Long-term Extension Study of PCI-32765 (Ibrutinib) (CAN3001)

Studying the long-term effects of Ibrutinib in people who were on previous trials for the drug that have now closed

Expected to end: 29/01/2027

A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies

Testing a new treatment to understand it’s efficacy and the best dose for patients

Expected to end: 31/03/2028

Rituximab and Ibrutinib (RI) versus Dexamethasone, Rituximab and Cyclophosphamide (DRC) as Initial Therapy for Waldenström’s Macroglobulinaemia (RAINBOW)

Is ibrutinib and rituximab a more effective first-line treatment than the current standard first-line treatment for people with WM?

Expected to end: 01/03/2030

A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies

The first trial in humans for a new type of BTK degrader

Expected to end: 01/01/2028

An Open-label, Phase 2 Study of ACP-196 in Subjects With Waldenström Macroglobulinemia

Measuring the safety and efficacy of Acalabrutinib in people with WM

Expected to end: 31/12/2026

A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL

Understanding the best dosage for a BTK inhibitor called Pirtobrutinib

Expected to end: 01/01/2028

Study of Bcl-2 Inhibitor Sonrotoclax (BGB-11417) in Participants With Mature B-Cell Malignancies

Understanding the dosage and safety of a new type of treatment

Expected to end: 30/08/2027